Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Vesole

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
Leukemia & Lymphoma|June 25, 2011
Predicting outcomes in multiple myeloma: do we really need another model?David H Vesole
Blood|December 9, 2003
Transplantation for multiple myeloma: who, when, how often? Patient selection and goalsDavid H Vesole
Oncology (Williston Park, N.Y.)|October 17, 2002
Multiple myeloma: role of allogeneic transplantationSandeep Pandit, David H Vesole
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Pretransplant induction regimens for multiple myelomaDavid H Vesole, David S Siegel
Current Treatment Options in Oncology|April 30, 2003
Management of renal dysfunction in multiple myelomaSandeep R Pandit, David H Vesole
Oncology (Williston Park, N.Y.)|February 1, 2007
Stem cell transplant for first relapse from the multiple myeloma research foundationKenneth C Anderson, David H Vesole
Oncology (Williston Park, N.Y.)|July 18, 2022
Recent Advancements and Future Directions in Frontline Treatment of Multiple MyelomaKimberley R Doucette, David H Vesole
Expert Opinion on Investigational Drugs|August 1, 2009
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agentBritt Erika Hanson, David H Vesole
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trialsDavid H Vesole, David S Siegel
Blood|August 2, 2003
High-dose therapy in multiple myelomaJoan Bladé, David H Vesole, Gertz Morie
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|June 25, 2011
Predicting outcomes in multiple myeloma: do we really need another model?David H Vesole
Blood|December 9, 2003
Transplantation for multiple myeloma: who, when, how often? Patient selection and goalsDavid H Vesole
Oncology (Williston Park, N.Y.)|October 17, 2002
Multiple myeloma: role of allogeneic transplantationSandeep Pandit, David H Vesole
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Pretransplant induction regimens for multiple myelomaDavid H Vesole, David S Siegel
Current Treatment Options in Oncology|April 30, 2003
Management of renal dysfunction in multiple myelomaSandeep R Pandit, David H Vesole
Oncology (Williston Park, N.Y.)|February 1, 2007
Stem cell transplant for first relapse from the multiple myeloma research foundationKenneth C Anderson, David H Vesole
Oncology (Williston Park, N.Y.)|July 18, 2022
Recent Advancements and Future Directions in Frontline Treatment of Multiple MyelomaKimberley R Doucette, David H Vesole
Expert Opinion on Investigational Drugs|August 1, 2009
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agentBritt Erika Hanson, David H Vesole
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trialsDavid H Vesole, David S Siegel
Blood|August 2, 2003
High-dose therapy in multiple myelomaJoan Bladé, David H Vesole, Gertz Morie
Pageof 15